abstract |
The present invention relates to the field of immune system diseases. In particular, the present invention relates to the use of a soluble CTLA4 mutant molecule, including L104EA29Ylg, for inhibiting T-cell function but not T-cell depletion by contacting B7-positive cells with the soluble CTLA4 mutant molecule, and thereby treating the immune system diseases. The soluble CTLA4 mutant molecules used all comprise a CTLA4 extracellular domain. The disorders treated include graft vs. host disease, immune disorders associated with graft transplantation rejection, chronic rejection, and tissue or cell allo- or xenographs. |